U.S. HIV/AIDS Therapies Markets

Published by: Frost & Sullivan

Published: Jan. 27, 2003

Table of Contents

1 Executive Summary

A. Executive Summary

1 Executive Summary

2 Introduction

A. HIV/AIDS: Definition and Classification

1 Report Scope

2 The Human Immunodeficiency Virus

3 Acquired Immuno-Deficiency Syndrome(AIDS)

4 Etiology and Demography

5 Diagnostic Tests

6 Overview of HIV/AIDS Therapies

7 Highly Active Antiretroviral Therapy(HAART)

B. Challenges and Strategies

1 Overview of Challenges

2 Challenge 1: Higher Drug Resistance

3 Challenge 2: Inconsistent Patient Adherence

4 Challenge 3: Higher Pill Burdens

5 Challenge 4: Drug-Induced Dyslipidemia

6 Challenge 5: Patients' Lower Tolerability

7 Challenge 6: Limited Funds and High Drug Prices

C. Market Dynamics

1 Market Drivers

2 Market Restraints

3 Pricing Trends

4 Demand Analysis

5 Revenue Forecasts

6 Market Engineering Analysis

D. Competitive Analysis

1 Competitive Structure

2 Market Share Analysis

E. Market Engineering Awards

1 Marketing Strategy Leadership Award

2 Product Innovation Award

3 Business Development Strategy Award

3 Nucleoside Reverse Transcriptase Inhibitors Market

A. Market Overview

1 Introduction

2 Product Analysis - Existing NRTIs

3 Product Analysis - Pipeline NRTIs

4 Market Drivers

5 Market Restraints

B. Market Dynamics

1 Pricing Analysis

2 Revenue Forecasts

3 Market Engineering Analysis

C. Competitive Analysis

1 Competitive Structure

2 Market Share Analysis

4 Protease Inhibitors Market

A. Market Overview

1 Introduction

2 Product Analysis - Existing Protease Inhibitors

3 Product Analysis - Pipeline Protease Inhibitors

4 Market Drivers

5 Market Restraints

B. Market Dynamics

1 Pricing Analysis

2 Revenue Forecasts

3 Market Engineering Analysis

C. Competitive Analysis

1 Competitive Structure

2 Market Share Analysis

5 Non-Nucleoside Reverse Transcriptase Inhibitors Market

A. Market Overview

1 Introduction

2 Product Analysis - Existing NNRTIs

3 Product Analysis - Pipeline NNRTIs

4 Market Drivers

5 Market Restraints

B. Market Dynamics

1 Pricing Analysis

2 Revenue Forecasts

3 Market Engineering Analysis

C. Competitive Analysis

1 Competitive Structure

2 Market Share Analysis

6 Future HIV/AIDS Therapies

A. Pipeline ARV Drugs in Novel Categories

1 HIV Entry Inhibitors

2 Immune-Based Therapies

3 Miscellaneous Antiretroviral Therapies

4 Market Share Analysis

B. HIV/AIDS Vaccines

1 Overview

2 Vaccines in Phase III Stage

3 Other Pipeline Vaccines

Abstract

Antiretroviral (ARV) drugs that prevent HIV replication are always recommended in combinations guided by the principles of highly active antiretroviral therapy (HAART), which seeks to reduce resistance, adverse reactions, and pill burdens, while improving efficacy. Existing categories- nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)- remain at the core of HAART, with several ARV drugs in the pipeline. However, drugs under development in new categories such as entry inhibitors, immune-based therapies, zinc finger inhibitors, and integrase inhibitors have the potential to transform this dynamic market. Established and recent participants can look forward to exciting growth prospects in addressing the strong need for new antiretroviral drugs in existing and novel categories.

This Frost & Sullivan research is a detailed study of the HIV/AIDS therapies markets in the United States. It segments the market as follows: NRTIs, NNRTIs, PIs, and future therapies in novel categories. This report offers an in-depth product analysis of current antiretroviral drugs as well as those in the pipeline. It discusses major drivers, restraints, and challenges governing the market and offers strategic recommendations to overcome them.

Expanding and Alert HIV Population Boosts Demand for HIV/AIDS Therapies

Of the almost 900,000 HIV-infected people in the United States, nearly 25 percent remain unaware and undiagnosed. This is likely to generate greater demand for HIV/AIDS therapies, as more infected people are diagnosed and come forward to be treated. Effective ARV therapy will reduce mortality rates increasing the number of persons living with AIDS and seeking continual treatment.

Better and rapid testing leading to increased diagnosis as well as enhanced awareness have resulted in more people registering for tests and treatment. "Due to major efforts by HIV/AIDS-related help groups, the industry and the media, the reported cases of HIV/AIDS and consequently, the number of HIV positive people opting for treatment will increase," says the analyst.

Coordinated Communication Efforts of Help Groups, Federal Agencies, and Others Benefit Market Participants

The Red Ribbon Project has played an integral role in inspiring end users and increasing their faith in available HIV/AIDS therapies as well as those under clinical trials. It has supported the lobbying efforts of help groups to increase funding for AIDS-related services and research. Several associations and help groups are committed to educating its members on the prevention and treatment of the disease. "The powerful symbolism of the Red Ribbon is probably the most important driver of this market that heightens the hope for cure, and the urgency for treatment," says the analyst.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.